Press Releases

Date Title
Mar 02, 2023 Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update
- Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study – – Confirmed Response in Non-H3 K27M Recurrent Glioblastoma Patient During ONC206 Dose Escalation – – Strong Balance Sheet with $266 Million in Cash at Year-End and No
Feb 28, 2023 Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference
DURHAM, N.C. , Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman , Chief Executive Officer, will participate
Feb 23, 2023 Chimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023
DURHAM, N.C. , Feb. 23, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on
Jan 05, 2023 Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference
DURHAM, N.C. , Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman , Chief Executive Officer, will present a
Displaying 11 - 14 of 14
  • Print
  • Email Alerts
  • RSS Feeds
  • Search
  • Share
scroll back to top of page